iSpecimen

ISPC

Börsenwert 2,31 Mio. $

Company coordinates collection of more than 1,700 human specimens to support new laboratory testing capabilities Woburn, Massachusetts--(Newsfile Corp. - September 29, 2026) - iSpecimen, a provider of human biospecimens, is supporting a hospital laboratory in the validation of a new chemistry analyzer for clinical use. For the project, iSpecimen identified a healthcare system already using the same analyzer and is coordinating the collection of more than 1,700 serum, plasma, cerebrospinal fluid (CSF), and urine specimens for use in the hospital's validation process.

Woburn, MA, Aug. 20, 2026 (GLOBE NEWSWIRE) -- iSpecimen, a provider of human biospecimens, recently completed an international cancer research project involving hundreds of cancer blood specimens, with the samples shipped within three weeks of receiving the purchase order. The project involved the coordination of large-scale biospecimen sourcing and fulfillment on an accelerated timeline.

WOBURN, Mass., Aug. 07, 2026 (GLOBE NEWSWIRE) -- iSpecimen Inc. (Nasdaq: ISPC) (“iSpecimen” or the “Company”), an online global marketplace that connects scientists requiring biospecimens for medical research with a network of healthcare specimen providers, announced today the closing of its previously announced public offering of an aggregate of 996,231 shares of the Company's common stock and pre-funded warrants to purchase up to an aggregate of 2,849,923 shares of common stock, for an aggregate purchase price of approximately $5.0 million. The Company intends to use the proceeds of the offering for repayment of outstanding liabilities, potential acquisitions of assets or investments in businesses, products and technologies and for marketing and advertising services. The remainder of the proceeds will be used for working capital purposes.

Transaction Marks E.F. Hutton's Third Capital Markets Engagement with iSpecimen Since December 2025 Transaction Marks E.F. Hutton's Third Capital Markets Engagement with iSpecimen Since December 2025

NEW YORK, May 12, 2026 (GLOBE NEWSWIRE) -- E.F. Hutton & Co. (“E.F. Hutton”), an investment banking and financial advisory firm headquartered in New York City, today announced that it acted as the exclusive placement agent in connection with a $2.5 million private placement for iSpecimen Inc. (Nasdaq: ISPC) (“iSpecimen” or the “Company”), an online global marketplace that connects scientists requiring biospecimens for medical research with a network of healthcare specimen providers.

May 8, 2026 WOBURN, Mass., May 08, 2026 (GLOBE NEWSWIRE) -- iSpecimen Inc. (Nasdaq: ISPC) (“iSpecimen” or the “Company”), an online global marketplace that connects scientists requiring biospecimens for medical research with a network of healthcare specimen providers, today announced that it has priced a private placement with accredited investors for aggregate gross proceeds of approximately $2.5 million, before deducting fees to the placement agent and other offering expenses payable by the Company.

Woburn, Massachusetts--(Newsfile Corp. - April 24, 2026) - iSpecimen Inc. (NASDAQ: ISPC) ("iSpecimen" or the "Company"), an online global marketplace that connects scientists requiring biospecimens for medical research with a network of healthcare specimen providers, announced today that it will effect a reverse stock split of its issued and outstanding shares of common stock, par value $0.0001 per share, as well as any shares of common stock held by the Company in treasury, at a ratio of 1-for-40. The reverse stock split will become effective at 4:30 p.m.

Woburn, Massachusetts--(Newsfile Corp. - April 9, 2026) - iSpecimen (NASDAQ: ISPC), an online marketplace for human biospecimens, has implemented a streamlined shipping model that enables direct shipment of biospecimens from supplier sites to customers, both domestically and internationally. By reducing reliance on centralized hub processing, the new model simplifies logistics and eliminates multi-step routing.

Woburn, Massachusetts--(Newsfile Corp. - March 16, 2026) - iSpecimen Inc. (NASDAQ: ISPC) (the "Company"), a leading provider of human biospecimens for research, is proud to announce recent milestones that demonstrate the responsiveness and capabilities of its site network. Over the past several months, iSpecimen has been actively supporting customer research by sourcing high-quality respiratory samples, with a particular focus on influenza.

Strengthens iSpecimen's next-generation marketplace platform Woburn, Massachusetts--(Newsfile Corp. - March 12, 2026) - iSpecimen Inc. (NASDAQ: ISPC) (the "Company"), a leading technology marketplace connecting researchers with biospecimen suppliers, today announced the launch of its new AI-powered Inventory Agent, a purpose-built tool designed to help accelerate the process of reviewing incoming biospecimen requests and matching them with available inventory across its global supplier network. The internally developed AI agent analyzes incoming request criteria and is designed to identify potential biospecimen matches, enabling the iSpecimen team to respond to research inquiries with greater speed and precision.